BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20167839)

  • 1. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
    Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin G; Butera JN
    Oncologist; 2010; 15(3):293-9. PubMed ID: 20167839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paying more than lip service to an oral lesion: a case of plasmablastic lymphoma.
    Moayedi Y; Venos ES; Ghaffar H; Gough KA; Hicks LK
    BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22802569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-negative plasmablastic lymphoma: not in the mouth.
    Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin GA; Butera JN
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):185-9. PubMed ID: 21575922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
    Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.
    Castillo JJ; Furman M; Beltrán BE; Bibas M; Bower M; Chen W; Díez-Martín JL; Liu JJ; Miranda RN; Montoto S; Nanaji NM; Navarro JT; Seegmiller AC; Vose JM
    Cancer; 2012 Nov; 118(21):5270-7. PubMed ID: 22510767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
    Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
    Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
    J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
    Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
    Boulanger E; Agbalika F; Maarek O; Daniel MT; Grollet L; Molina JM; Sigaux F; Oksenhendler E
    Hematol J; 2001; 2(3):172-9. PubMed ID: 11920242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
    Castillo J; Pantanowitz L; Dezube BJ
    Am J Hematol; 2008 Oct; 83(10):804-9. PubMed ID: 18756521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
    Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
    J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
    J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.
    Rapiti N; Peer N; Abdelatif N; Rapiti P; Moosa Y
    HIV Med; 2022 Sep; 23(8):837-848. PubMed ID: 35229978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS.
    Basavaraj A; Kadam M; Kadam DB
    J Assoc Physicians India; 2016 May; 64(5):71-72. PubMed ID: 27735156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
    Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
    Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.